Zobrazeno 1 - 10
of 258
pro vyhledávání: '"Yuka, Fujita"'
Autor:
Kana Hashimoto, MD, Daisuke Morinaga, MD, Hajime Asahina, MD, PhD, Mina Ishidoya, MD, Hajime Kikuchi, MD, PhD, Hiroshi Yokouchi, MD, PhD, Toshiyuki Harada, MD, PhD, Osamu Honjo, MD, Ryota Shigaki, MD, Taichi Takashina, MD, PhD, Yuka Fujita, MD, PhD, Mamoru Takahashi, MD, PhD, Yasutaka Kawai, MD, Ryotaro Kida, MD, Kenichiro Ito, MD, Noriaki Sukoh, MD, PhD, Ayumu Takahashi, MD, PhD, Fumihiro Hommura, MD, PhD, Yoshihito Ohhara, MD, PhD, Megumi Furuta, MD, PhD, Satoshi Konno, MD, PhD, Yukio Hosomi, MD, PhD, Satoshi Oizumi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 11, Pp 100715- (2024)
Introduction: Oligometastasis and oligoprogression (OP) has not been adequately defined in extensive-stage SCLC (ES-SCLC) and may be a good indication for adding local treatment. Therefore, this multicenter study aimed to investigate the prognostic i
Externí odkaz:
https://doaj.org/article/6a9e9af6ebb84315b50bcf56a349d75d
Autor:
Haruna Sakanoue, Hirosuke Yamaji, Sayaka Okamoto, Kumi Okano, Yuka Fujita, Shunichi Higashiya, Takashi Murakami, Shozo Kusachi
Publikováno v:
Journal of Arrhythmia, Vol 40, Iss 2, Pp 289-296 (2024)
Abstract Background Postoperative nausea and vomiting (PONV) following atrial fibrillation (AF) ablation can cause considerable distress. Aim Continuous intravenous propofol sedation with adaptive servo‐ventilation (ASV) with or without an analgesi
Externí odkaz:
https://doaj.org/article/5ba02f5f41a94b87acd1d2340c324513
Autor:
Mototsugu Shimokawa, Masaki Kanazu, Ryusei Saito, Masahide Mori, Atsuhisa Tamura, Yoshio Okano, Yuka Fujita, Takeo Endo, Mitsuru Motegi, Shohei Takata, Toshiyuki Kita, Noriaki Sukoh, Fumitaka Mizuki, Mitsuhiro Takenoyama, Shinji Atagi
Publikováno v:
Thoracic Cancer, Vol 14, Iss 17, Pp 1597-1605 (2023)
Abstract Background Previous trials suggest that older adults with non‐small cell lung cancer (NSCLC) derive benefit from platinum doublet combination therapy, but its superiority is controversial. Although geriatric assessment variables are used t
Externí odkaz:
https://doaj.org/article/76404a9fd6d2454e84c0f25fef6834a6
Autor:
Yoshihito Kogure, MD, PhD, Akiko Kada, MPH, Hiroya Hashimoto, PhD, Shinji Atagi, MD, Yuichi Takiguchi, MD, Hideo Saka, MD, Noriyuki Ebi, MD, Akira Inoue, MD, Takayasu Kurata, MD, Yuka Fujita, MD, Yoichi Nishii, MD, Hidetoshi Itani, MD, Takeo Endo, MD, Akiko M. Saito, MD, Takuo Shibayama, MD, Nobuyuki Yamamoto, MD, Akihiko Gemma, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 6, Pp 100514- (2023)
Introduction: In the CAPITAL study, a randomized phase 3 study, wherein carboplatin plus nab-paclitaxel treatment was compared with docetaxel treatment for older patients with squamous-cell lung cancer, the former became the new standard of care for
Externí odkaz:
https://doaj.org/article/4876c2feeaf34060b78e84539b872f0e
Autor:
Gaku Yamamoto, Hajime Asahina, Osamu Honjo, Toshiyuki Sumi, Atsushi Nakamura, Kenichiro Ito, Hajime Kikuchi, Fumihiro Hommura, Ryoichi Honda, Keiki Yokoo, Yuka Fujita, Satoshi Oizumi, Ryo Morita, Yasuyuki Ikezawa, Hisashi Tanaka, Nozomu Kimura, Takaaki Sasaki, Noriaki Sukoh, Taichi Takashina, Toshiyuki Harada, Hirotoshi Dosaka-Akita, Hiroshi Isobe, the Hokkaido Lung Cancer Clinical Study Group Trial
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line th
Externí odkaz:
https://doaj.org/article/30fdf5599db64195b591b2c71f3f2250
Autor:
Hisashi Tanaka, Yukihiro Hasegawa, Yuka Fujita, Atsushi Nakamura, Eiki Kikuchi, Yasutaka Kawai, Toshiyuki Harada, Naomi Watanabe, Hiroshi Yokouchi, Kazuhiro Usui, Ryota Saito, Hiroshi Watanabe, Tomomi Masuda, Tatsuro Fukuhara, Keita Kudo, Ryoichi Honda, Satoshi Oizimi, Makoto Maemondo, Akira Inoue, Naoto Morikawa
Publikováno v:
Thoracic Cancer, Vol 12, Iss 14, Pp 2113-2121 (2021)
Abstract Background A cisplatin plus irinotecan (CPT‐11) regimen is used for patients with extensive disease small cell lung cancer (ED‐SCLC). Amrubicin (AMR) is primarily used for relapsed SCLC. The HOT1401/NJLCG1401 trial, an open‐label rando
Externí odkaz:
https://doaj.org/article/c0e9bc75e14647f5afcebfe007cf88f5
Autor:
Akira Minami, Yuka Fujita, Jun Goto, Ayano Iuchi, Kosei Fujita, Yasuyo Mikami, Mako Shiratori, Ami Ishii, Samir Mitragotri, Yasunori Iwao, Hiroaki Kanazawa, Yuuki Kurebayashi, Tadanobu Takahashi, Tadamune Otsubo, Kiyoshi Ikeda, Takashi Suzuki
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Reduction of elastin in the skin causes various skin diseases as well as wrinkles and sagging with aging. Sialidase is a hydrolase that cleaves a sialic acid residue from sialoglycoconjugate. Cleavage of sialic acid from microfibrils by the
Externí odkaz:
https://doaj.org/article/b206dd55f73d4226b1ced499d9b7d30c
Autor:
Hiroshi Yokouchi, Hiroshi Nishihara, Toshiyuki Harada, Toraji Amano, Takayuki Ohkuri, Shigeo Yamazaki, Hajime Kikuchi, Satoshi Oizumi, Hidetaka Uramoto, Fumihiro Tanaka, Masao Harada, Kenji Akie, Fumiko Sugaya, Yuka Fujita, Kei Takamura, Tetsuya Kojima, Mitsunori Higuchi, Osamu Honjo, Yoshinori Minami, Naomi Watanabe, Masaharu Nishimura, Hiroyuki Suzuki, Hirotoshi Dosaka-Akita, Hiroshi Isobe
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
OX40 (CD134) is a co-stimulatory molecule mostly expressed on activated T lymphocytes. Previous reports have shown that OX40 can be an immuno-oncology target and a clinical biomarker for cancers of various organs. In this study, we collected formalin
Externí odkaz:
https://doaj.org/article/18254917a1194ec3b68c770c8b7a5de6
Autor:
Yuka Fujita
Publikováno v:
Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening). 32:117-120
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b41f9c7cb79e69357d4b09fa6bddf68
https://doi.org/10.3804/jjabcs.32.117
https://doi.org/10.3804/jjabcs.32.117
Autor:
Tatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, Kana Watanabe, Shunichi Sugawara, Shunichiro Iwasawa, Yoshio Tsunezuka, Ou Yamaguchi, Prof Morihito Okada, Kozo Yoshimori, Ichiro Nakachi, Prof Akihiko Gemma, Koichi Azuma, Futoshi Kurimoto, Yukari Tsubata, Yuka Fujita, Hiromi Nagashima, Gyo Asai, Satoshi Watanabe, Masaki Miyazaki, Prof Koichi Hagiwara, Prof Toshihiro Nukiwa, Prof Satoshi Morita, Prof Kunihiko Kobayashi, Prof Makoto Maemondo
Publikováno v:
EBioMedicine, Vol 57, Iss , Pp 102861- (2020)
Summary: Background: The NEJ026 Phase 3 study demonstrated that erlotinib and bevacizumab (BE)-treated NSCLC patients with EGFR mutations had significantly better progression-free survival (PFS) than those treated with erlotinib alone (E). This study
Externí odkaz:
https://doaj.org/article/6f1997f9abf34fafabd3f2040e531e6b